Company Name: Prothena Corporation plc
Prothena Corporation plc is a late-stage clinical biotechnology company. The company is engaged in the discovery, development and commercialization of protein immunotherapies for diseases involving amyloid or cell adhesion. The company’s lead product candidate is a monoclonal antibody designed to treat AL amyloidosis.
Ticker Symbol: PRTA (NASDAQ)
Company Website: www.prothena.com
Headquarters: Dublin, Ireland